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Abstract 31"
Context: In active Cushing’s syndrome (CS), patients suffer from endothelial dysfunction and 32"
premature atherosclerosis. However, it is uncertain to what extent vascular health recovers after long-33"
term remission. This is highly relevant as this topic relates to future development of cardiovascular 34"
disease. 35"
Objective: To investigate whether micro- and macrovascular health is impaired after long-term 36"
remission of CS, in patients with no or adequately treated co-morbidities.  37"
Design and setting: Cross-sectional case–control study in two tertiary referral centers. 38"
Patients and main outcome measures: 63 patients (remission of CS for ≥ 4 years) and 63 healthy, 39"
well-matched controls were compared. In group A (58 patients and 58 controls) serum biomarkers 40"
associated with endothelial dysfunction, intima media thickness, pulse wave velocity and pulse wave 41"
analysis were studied. In group B (14 patients and 14 controls) endothelium-dependent and  42"
-independent vasodilatation was studied in conduit arteries (flow mediated dilation of the brachial 43"
artery) and forearm skeletal muscle resistance arteries (vasodilator response to intra-arterial 44"
acetylcholine, sodium-nitroprusside and NG-monomethyl-L-arginine using venous occlusion 45"
plethysmography).  46"
Results: There were no significant differences between the outcome measures of vascular health of 47"
patients and controls in group A and B.  48"
Conclusion: Vascular health of patients in long-term remission of Cushing’s syndrome seems to be 49"
comparable to that of healthy gender-, age and BMI matched controls, provided that the patients have 50"
no, or adequately controlled co-morbidities. Therefore, the effects of hypercortisolism per se on the 51"
vasculature may be reversible. This accentuates the need for stringent treatment of metabolic co-52"
morbidities in these patients. 53"
  54"
Introduction 55"
Patients with chronic hypercortisolism due to endogenous Cushing’s syndrome (CS) have a 56"
very high mortality rate, with an estimated 5-year survival of 50% in untreated patients (1). 57"
Cardiovascular disease is the main cause of mortality (1). Multiple studies have shown that endothelial 58"
function is impaired in these patients (2-5), with an increased incidence of atherosclerosis (6, 7). It has 59"
been suggested that this is mainly caused by the fact that most patients with CS have centripetal 60"
obesity, impaired glucose tolerance, systemic hypertension, hypercoagulability and dyslipidemia(8). 61"
All these factors are associated with impaired endothelial function and premature atherosclerosis, 62"
especially if they occur simultaneously (9). In addition, one should realize that the hypercortisolism 63"
itself has a direct effect on the vasculature (via both the glucocorticoid and the mineralocorticoid 64"
receptor) (10, 11).  65"
Successful surgical treatment of CS, resulting in normalization of cortisol secretion, 66"
significantly decreases cardiovascular risk and reduces mortality rate (1, 12). However, it is unclear to 67"
what extent vascular health recovers in patients in long-term remission of CS. Full recovery is not self-68"
evident, since centripetal obesity and an adverse adipokine profile (which is known to be associated 69"
with endothelial dysfunction and eventually macrovascular disease (13, 14)) persists even after long-70"
term remission of CS (15, 16). Furthermore, it is questionable if the direct effects of hypercortisolism 71"
on the vasculature are fully reversible.  72"
A number of studies have previously investigated vascular health in small groups of patients in 73"
remission of CS (17-23). These studies reported inconsistent results, which may partly be explained by 74"
the small group size and/or selection of single markers of vascular health that, therefore, cannot 75"
provide a broad insight.  76"
The aim of this study was to investigate micro- and macrovascular health in a large group of 77"
patients in long-term remission of CS with adequately treated co-morbidity if present, in comparison 78"
with a matched healthy control group. We measured serum biomarkers associated with endothelial 79"
dysfunction, performed gold standard measurements of endothelial function and investigated the 80"
presence of overt atherosclerosis.   81"
Subjects and methods 82"
Subjects 83"
All adult patients of Radboud University Medical Center Nijmegen and Leiden University 84"
Medical Center, who had been successfully treated for CS (caused by either an ACTH-producing 85"
pituitary adenoma or a benign adrenal adenoma) and were in remission for at least four years, were 86"
eligible for inclusion in this multi-center cross-sectional matched case-control study. Remission was 87"
defined as absence of clinical signs and symptoms of hypercortisolism and suppression of plasma 88"
cortisol to ≤50 nmol/l after 1 mg dexamethasone overnight or, if a patient had received radiotherapy of 89"
the pituitary gland, a 24-h urinary free cortisol value of <240 nmol/24 h for men or <150 nmol/24 h for 90"
women. The medical records of all patients were retrospectively reviewed to assess clinical data 91"
regarding the etiology of CS, the type of treatments that patients had received, duration of remission, 92"
presence of hormonal deficiencies and co-morbidities. Information on the treatment of co-morbidities 93"
of the patients can be found in supplemental Table 1.  94"
 In our study we investigated 63 patients, divided in 2 different patient groups. Group A 95"
comprised 58 patients, and group B 14 patients. Nine patients were included in both groups.  96"
Group A was the same group of patients that we previously described in our study on body 97"
composition, extensive information about the patient selection can be found in that article (16). In 98"
short: the following exclusion criteria were applied: untreated (or inadequately treated) hormonal 99"
deficiencies, active malignancy or systemic therapy for malignancy in the past, severe inflammatory 100"
diseases and psychiatric pathology. Each patient was matched to a control subject with the same 101"
gender, age (±2 years), and body mass index (BMI, ±2 kg/m2). Control subjects, recruited via 102"
advertisements in a local newspaper, had to be healthy and without current use of medication.  103"
For the second group of patients (group B, n=14), even stricter exclusion criteria were used: 104"
All subjects with hormonal deficiencies, except for adequately treated hypothyroidism (free T4 range 105"
8.0-22.0 pmol/l), were excluded. Furthermore, besides the co-morbidities applied for exclusion in  106"
Group A, all patients with co-morbidities that are known to affect vascular function or who used 107"
medication that may interfere with the cardiovascular system were excluded. In addition to gender, age 108"
and BMI, the healthy control subjects were also matched for smoking, ethnicity, and physical activity 109"
levels (estimated via metabolic equivalent of task scores and measured for one week with a SenseWear 110"
Pro ArmbandTM (Body Media, Pittsburg, USA)). Female controls were matched for estrogen status and 111"
oral contraceptive use.  112"
The Medical Ethics Committees of our institutions approved this study and all participants 113"
provided written informed consent prior to participation. 114"
 115"
 116"
Methods 117"
All subjects refrained from smoking, alcohol, caffeine, chocolate and vitamin C for at least 18 118"
hours, and vigorous physical exercise for at least 24 hours before testing. Subjects fasted at least 6 119"
hours before testing.  120"
Biochemical markers associated with endothelial dysfunction (group A) 121"
Serum concentrations of plasminogen activator inhibitor-1 (PAI-1), intracellular adhesion 122"
molecule-1 (ICAM-1) and soluble E-selectin were measured by Multiplex Fluorescent Bead 123"
Immunoassays (xMAP technology, Millipore, Billerica, MA, USA) and a Bio-plex microbead 124"
analyzer (Luminex, Austin, TX, USA) according to the manufacturer’s protocol. Serum concentrations 125"
of vascular cell adhesion molecule-1 (VCAM-1) were determined by an enzyme-linked 126"
immunosorbent assay (R&D Systems, Minneapolis, MN, USA).  127"
 128"
Non-invasive measurements of atherosclerosis and arterial stiffness (group A) 129"
Measurements of carotid intima media thickness (cIMT), pulse wave velocity (PWV) and pulse wave 130"
analysis (PWA) were performed according to a highly standardized protocol and performed by the 131"
same experienced technician (SH) in all patients (24). Mean cIMT was calculated from the mean of 132"
four measured segments of the vessel: far wall left, far wall right, near wall left and near wall right. 133"
Subsequently the presence of plaques and size was evaluated at the level of the common, internal and 134"
external carotid arteries. Plaque was defined as any focal protrusion above the surrounding intima of at 135"
least 1.5 x mean cIMT. 136"
PWV and PWA were measured with applanation tonometry, using SphygmoCor system 137"
version 7.1 (Atcor Medical, Sydney. Australia). Central arterial pressure (CAP) and central systolic 138"
pressure (CSP) were derived and central augmentation index (AIx) was calculated. As AIx is 139"
influenced by heart rate, an index normalized for a heart rate of 75 beats/min was used. To determine 140"
pulse wave velocity, pulse wave forms were recorded at the right carotid artery and left femoral artery 141"
sequentially. Wave-transit time was calculated using the R-wave of a simultaneously recorded ECG as 142"
a reference frame. The coefficient of variation (CV) for measuring PWV is 5-10%(25). 143"
 144"
Endothelial function (group B) 145"
Brachial artery flow mediated dilation (FMD) is widely accepted to reflect endothelium-146"
dependent and largely nitric oxide-mediated function of conduit arteries (26). Measurements were 147"
performed by two experienced vascular sonographers (DT & TS). A 10 MHz multifrequency linear 148"
array probe attached to a high-resolution ultrasound machine (T3000; Terason, Burlington, 149"
Massachusetts, USA) was used for imaging of the brachial artery in the distal third of the upper arm. 150"
Subjects rested in a supine position for at least 15 minutes to enable baseline assessment of arterial 151"
diameter and blood flow. The arm was extended and positioned at an 80o angle from the torso. A rapid 152"
inflation pneumatic cuff (Hokanson, Bellevue, Washington, USA) was positioned on the forearm 153"
immediately distal to the olecranon to provide the forearm ischemic stimulus. After obtaining an 154"
optimal image, the probe was manually stabilized and the ultrasound parameters were set to optimize 155"
longitudinal B-mode imaging of the lumen-arterial wall interface. Continuous Doppler velocity was 156"
measured using the lowest possible insonation angle (< 60o). The forearm cuff was inflated to 157"
220mmHg for 5 minutes. Diameter and flow recordings resumed 30 seconds prior to cuff deflation and 158"
continued for 5 minutes thereafter. Following a 15 minutes resting period, a 1-minute baseline 159"
recording of the brachial artery diameter and flow was taken. Subsequently, brachial artery 160"
endothelium-independent vasodilatation was examined after administration of a single spray of 161"
sublingual glyceryl trinitrate (GTN), which serves as a direct nitric oxide (NO) donor, to detect 162"
endothelium-independent vasodilator capacity. This was followed by 5 minutes of continuous 163"
recording of brachial artery diameter and blood flow. Post-test analysis of brachial artery diameter was 164"
performed using customized edge-detection and wall tracking software (27). Baseline diameter, flow 165"
and shear rate were calculated as the mean of data acquired across the 1-minute preceding the cuff 166"
inflation period. Peak diameter following cuff deflation was automatically detected as previously 167"
described (28). FMD was calculated as the percentage rise of this peak diameter from the preceding 168"
baseline diameter. The time to peak diameter (seconds) was calculated from the point of cuff deflation 169"
to the maximum post-deflation diameter. According to a recent study, inadequate scaling for FMD 170"
would be present if the upper confidence limit of the regression of the relation between logarithmically 171"
transformed base diameter and peak diameter is <1.0 (29). In such an event, FMD% is not an 172"
appropriate measure for the estimation of endothelial function. Data were checked for this 173"
phenomenon and subsequently allometric modeling was applied (29). Furthermore, FMD% was 174"
corrected for shear rate stimulus by adding this factor as a covariate in our analysis (30). The CV for 175"
measuring FMD with our protocol is 6.7% (30). 176"
Forearm blood flow measurements using venous occlusion plethysmography (FBF) – 177"
measures changes in blood flow (mainly determined by arteriolar resistance arteries in the muscle bed) 178"
in response to the infusion of intra-arterial vasoactive medications (25, 31). It therefore mainly 179"
assesses microvascular function. FBF was measured at the forearm using ECG-triggered bilateral 180"
strain-gauge venous occlusion plethysmography (31). Measurements were performed at 09:00 AM in 181"
a quiet, temperature controlled room (22°C). Mercury in silastic strain gauges placed around the 182"
widest portion of the upper third of both forearms were electrically coupled to a plethysmograph 183"
calibrated to measure normalized changes in volume. For each measurement, venous flow was 184"
occluded just proximal to the elbow by rapidly inflating a blood pressure cuff to 60mmHg. A wrist 185"
cuff was inflated to suprasystolic (220mmHg) pressures to exclude the hand circulation from the blood 186"
flow during the measurement starting 30 seconds prior to each measurement. A brachial artery catheter 187"
(angiocath 20G 1.88in, BD Angiocath) was inserted in the non-dominant arm after local anesthesia 188"
(lidocaine 2%), which was elevated slightly above the right atrium. Systolic blood pressure (BP), 189"
diastolic BP, mean arterial BP and heart rate were monitored continuously. The other arm was used as 190"
a control for systemic changes in vasomotor tone. To establish resting FBF, we administered 0.9% 191"
saline for 30 minutes. Vasoactive agent infusions were then started. Between each series of drug 192"
infusions, FBF was allowed to return to basal value during a 20 minute resting period, during which 193"
solvent (0.9% saline for acetylcholine (Ach) and 5% glucose for sodium-nitroprusside (SNP)) was 194"
infused to maintain a constant infusion rate. Ach (Miochol-E intraocular solution, 20mg, 195"
Bausch&Lomb; 1-2-4 µg/dL forearm volume/minute) was used to explore endothelium-dependent 196"
vasodilatation. SNP (25mg/ml, 2ml, Sigma-Aldrich; 0.2-0.4-0.8 µg/dL forearm volume/minute) was 197"
used to explore non-endothelium dependent vasodilatation. Finally, the nitric oxide synthase inhibitor 198"
NG-monomethyl-L-arginine (L-NMMA acetate 250 mg, Clinalfa® Basic, Bachem; 0.2-0.4-0.8 199"
µmol/dL forearm volume/minute) was infused to investigate the contribution of nitric oxide to basal 200"
vascular tone. Each substance-dose was infused for 5 minutes. FBF values are reported in milliliters 201"
per minute per 100ml of forearm volume. The baseline value is a mean of all measurements during the 202"
baseline measurement period. The values during drug infusion are a mean value of the last 6 203"
measurements per drug dose during a measurement period. Besides changes in blood flow, the blood 204"
flow ratio between the infusion and control arm was also calculated to correct for possible systemic 205"
effects(32)."The CV of FBF has been reported to be 8-10% during stimulation (31, 33). 206"
 207"
Statistical methods 208"
Data were analyzed using SPSS 20.0 statistical package for Windows (SPSS Inc, Chicago, 209"
IL). Data were expressed as mean ± SD, unless mentioned otherwise. Data distributions were analyzed 210"
and logarithmic transformation was performed before statistical testing when appropriate. Differences 211"
between patients and controls were tested with paired t-tests. Differences in categorical variables were 212"
analyzed using the χ2 test. In group A, stepwise backward multiple linear regression analysis was 213"
performed in the patients in order to detect clinical characteristics (etiology of CS, treatment strategies, 214"
presence of hormonal deficiencies, use of alcohol, smoking and co-morbidity) that are predictors of 215"
vascular function. A stepwise backward multiple linear regression analysis could not reliably be 216"
performed in group B because of the small sample size."P < 0.05 was considered statistically 217"
significant.  218"
Results 219"
Subject characteristics 220"
Table 1 shows the clinical characteristics of the patients and control subjects for group A, and 221"
Table 2 for group B. Intra-arterial cannulation was not successful in 3 patients and therefore the 222"
vasomotor response to intra-arterial drug infusions was investigated in 11 patients and controls (Table 223"
3). Adequate matching was reflected by the fact that no differences between patients and controls were 224"
present in both groups in gender, age and BMI. In group A patients only differed from controls with 225"
respect to smoking habits (more smokers in the patient group, P<0.05). 226"
 227"
Biochemical markers associated with endothelial dysfunction (Group A) 228"
No statistically significant differences in sVCAM-1, sICAM-1, E-selectin and PAI-1 were 229"
detected between patients and controls (Table 4).  230"
 231"
Non-invasive measurements of atherosclerosis and arterial stiffness (Group A) 232"
cIMT, PWV and CAP were not different between patients and controls (Table 4). A trend 233"
towards a statistically significant difference between the two groups was found for the AIx (P=0.056). 234"
Atherosclerotic plaques were detected in 10 patients and 10 controls. Plaque thickness was not 235"
significantly different between patients and controls. 236"
 237"
Endothelial function (Group B) 238"
No statistically significant differences were found between patients and controls in all FMD 239"
measurements (Table 4). Furthermore, no statistically significant differences were found between 240"
patients and controls regarding FBF or blood flow ratio responses at baseline or in response to the 241"
incremental doses of Ach, SNP and L-NMMA (all p >0.09) (Figure 1). 242"
  243"
Stepwise backward multiple linear regression analysis (Group A) 244"
Having DM predicted both a higher PWV (p=0.01) and higher sVCAM-1 levels (p<0.01). 245"
Subgroup analysis was performed for these two outcomes after exclusion of all matched patient-246"
control couples containing a patient with DM. This did not lead to significant differences between 247"
patients and controls (PWV p=0.796; sVCAM-1 p=0.865). Being a smoker was a predictor for a 248"
higher AIx (p<0.01). Subgroup analysis, after exclusion of all patient-control couples with a smoker, 249"
did not lead to a significant difference between patients and controls (AIx; p=0.078). 250"
Mineralocorticoid replacement was a predictor for higher E-selectin levels (p<0.01). Subgroup 251"
analysis, after exclusion of all couples with mineralocorticoid users, did not lead to a significant 252"
difference between patients and controls (E-selectin; p=0.913). Thyroid hormone replacement was a 253"
predictor for higher sVCAM-1 levels (p<0.01). Subgroup analysis after exclusion of couples with 254"
thyroid hormone users did not lead to a significant difference between patients and controls (sVCAM-255"
1; p=0.504).  256"
Discussion 257"
In this study we investigated micro- and macrovascular health in patients in long-term 258"
remission of CS who had no, or adequately treated co-morbidities using a combination of state-of-the-259"
art methods that has not been used in any previous study. We compared the patient group to a strictly 260"
one-to-one matched healthy control group. The main finding of our study is that the vascular health of 261"
patients in remission of CS is not significantly different from that seen in healthy control subjects 262"
matched for age, gender and BMI. This suggests that the direct effect of the period of hypercortisolism 263"
per se on the vasculature during the active disease is potentially reversible.  264"
Our findings that endothelial function recovers after remission of CS are in line with the study 265"
of Akaza et al. who investigated arterial endothelial function, with FMD, in a group of 12 patients 266"
shortly after remission (>3 months) of CS (22). They found that the impaired FMD in active CS was 267"
reversible after remission. Previous studies have shown that in vitro (cell culture) and in vivo (mouse) 268"
exposure of endothelial cells to glucocorticoids reduced the mRNA and/or protein content of 269"
endothelial NO synthase (34, 35) and reduced acetylcholine induced vasodilation of mouse resistance 270"
arteries (34) and rat aorta's (36). Therefore Akaza et al. [22] proposed that endothelial dysfunction in 271"
active CS is largely accounted for by the direct effect of hypercortisolism on vascular endothelium and 272"
that this is reversible after treatment.  273"
On the other hand, five other studies observed persistent impaired vascular health after 274"
remission of CS (17, 18, 20, 21, 23). However, in three of these studies there was either a short period 275"
of remission (17) or a pediatric study population (20, 21), so these studies are not comparable to our 276"
study. The studies reported by Colao et al. (18) and Barahona et al. (23) are more comparable. They 277"
both found a higher prevalence of atherosclerosis (measured by cIMT and presence of coronary artery 278"
disease detected by!computed tomography, respectively) compared to gender-, age- and BMI matched 279"
controls (18, 23). However, the patients in these studies had significantly more uncontrolled metabolic 280"
co-morbidities than their matched controls. In our study population the co-morbidities in Group A 281"
were adequately treated (16), and the patients in Group B had no known co-morbidities (except for 282"
treated hypothyroidism in 4 patients).  283"
A more recent publication of Colao et al. (19) also supports our findings. This study measured 284"
differences in cIMT and artery stiffness between active disease and one year after remission of CS in 285"
25 patients. There was a significant decrease in both variables between active disease and remission. 286"
After 1 year of remission both variables did not differ from a gender-, age- and BMI-matched control 287"
group as used in our study, but they were still higher than in controls with a lower BMI, matched only 288"
for gender and age. Moreover, diastolic blood pressure, LDL- and HDL-cholesterol levels were not 289"
different between the patients and the BMI-matched control group, but were significantly more 290"
adverse in the patients compared to the controls with a lower BMI. This emphasizes the importance of 291"
strict matching of each patient to a healthy individual of at least the same gender, age and BMI if one 292"
wants to investigate the effect of the previous period of hypercortisolism per se.  293"
Taken both our results and the previous findings into account, we conclude that patients in remission 294"
of CS, who are equally well-controlled for co-morbidities as age-, gender- and BMI matched healthy 295"
subjects, have comparable vascular health. This accentuates the need for stringent treatment of 296"
metabolic co-morbidities in these patients. Interestingly, the normalized vascular health seems to be 297"
irrespective of the fact that these patients have, as we have previously shown, a more centripetal 298"
adipose tissue distribution and adverse adipokine profile than their age-, gender- and BMI matched 299"
controls (16).  However, the patients in our study are relatively young, and vascular problems are more 300"
frequent as age increases. So even though we did not find indications for impaired vascular health at 301"
approximately 50 years of age, the fact that persistent central adiposity and an adverse adipokine 302"
profile are still present after long term remission of CS may mean patients still are at higher vascular 303"
risk later in life. !304"
As could be expected in group A, DM was associated with a higher PWV and higher sVCAM-305"
levels and smoking predicted a higher AIx but this did not affect the results of the total group. 306"
Moreover the trend towards a higher AIx in the patient group disappeared after correcting for 307"
smoking. Interestingly, except for an association between mineralocorticoid replacement and E-308"
selectin levels and the use of thyroid hormone replacement and VCAM-1 levels, no other patient 309"
characteristic (e.g. etiology of CS, treatment strategies, hormonal deficiencies) negatively affected 310"
vascular health parameters. This is in contrast to previous studies, where for example the use of 311"
glucocorticoid replacement therapy was associated with an increased cardiovascular risk (10).!312"
The major strength of our study is the broad spectrum of methodologies we used to investigate 313"
vascular health. All techniques are well validated and reproducible (25, 30, 31). Furthermore this is the 314"
first study that investigates endothelial function in patients in long-term remission of CS both in 315"
conduit arteries (FMD) and forearm resistance arteries (FBF, which is considered the gold standard 316"
procedure to measure endothelial dysfunction)(25). Thus we have investigated both the 317"
macrovasculature and the microvasculature.  318"
A possible limitation of this study is the relatively small sample size for group B. For FBF and 319"
FMD a number of about 10 patients was found to be adequate to detect a relevant difference (31, 37), 320"
and that however the subjects within our patient group (and thus also the control group) were more 321"
heterogeneous than in most previous studies leading to a greater SD. Therefore it is possible that we 322"
missed subtle but relevant differences. For example, there seems to be a non-significant trend towards 323"
a lower baseline FBF in the patients, which could indicate a reduction in muscle microvascular 324"
density. The latter might explain the exercise intolerance experienced by the patients (38). As blood 325"
flow in the skin and subcutaneous adipose tissue also contribute to FBF (31), future research 326"
measuring microvascular density in muscle biopsies will have to confirm whether skeletal muscle 327"
microvascular density is indeed lower in patients in remission of CS. !328"
A multitude of epidemiological studies reported an increased cardiovascular risk and 329"
standardized mortality (SMR) in patients in long-term remission of CS compared to an age and gender 330"
but not BMI matched reference population (1). As patients in remission of CS tend to have an overall 331"
higher BMI and waist circumference than the general population this may negatively affect 332"
cardiovascular risk and SMR. Furthermore these studies did not analyze potential differences between 333"
patients with- and without co-morbidities. However it may be possible that cardiovascular risk is still 334"
elevated in the healthiest patients in remission of CS because of a persistent effect of the prior 335"
hypercortisolism on other organs than the vasculature e.g. the myocardium (10, 11). However, this 336"
was not supported by a small study (39). Therefore further research is necessary to investigate these 337"
issues.  338"
In conclusion,"vascular health of patients in long-term remission of Cushing’s syndrome seems 339"
to be comparable to that of healthy gender-, age and BMI-matched controls, provided that the patients 340"
have no, or adequately controlled co-morbidities. Therefore, the effects of the previous 341"
hypercortisolism per se on the vasculature may be reversible. This accentuates the need for stringent 342"
individualized treatment of metabolic co-morbidities in these patients.  343"
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Figure legend: 450"
Figure 1: Change in forearm blood flow from baseline in response to infusion of different vasoactive 451"
agents in increasing dosages. 452"
"453"
Note:"On"group"level,"no"acute"vasomotor"responses"were"observed"in"the"control"arm"after"drug"infusions."Error"bars:"95%"CI."454"
"455"
  456"
Table 1: Group A: Clinical characteristics of patients in long-term remission of Cushing’s syndrome 457"
and healthy controls  458"
 Patients (n=58) Controls (n=58) P-value 
Gender (n): male/female 12/46 12/46  
Age: mean (± SD) (years) 50.8(12.3) 51.2(12.4) 0.863 
BMI: mean (± SD) (kg/m2) 26.5(4.2) 26.3(4.1) 0.793 
Duration of remission: median  
(± range) (years) 
13.6%±%8.0   
Smoking (yes/no) 
   Pack-years (± SD) 
14/44 
11.5(15.6) 
5/53 
6.9(13.9) 
0.024* 
Alcohol consumption: yes/no 10/48 13/45 0.485 
Treatment modalities: n (%) 
   Unilateral adrenalectomy 
   Bilateral adrenalectomy 
   Pituitary surgery 
   Pituitary radiotherapy 
 
19(32.8) 
12(20.7) 
38(65.5) 
13(22.4) 
 
- 
- 
- 
- 
 
- 
- 
- 
- 
 Hormonal deficiencies: n (%) 
   Glucocorticoid deficiency 
   Growth hormone deficiency 
   Thyroid hormone deficiency 
   Mineralocorticoid deficiency          
   Testosterone deficiency 
   Estrogen deficiency 1 
 
21(36.2) 
15(25.9) 
25(43.1) 
11(19.0) 
6/12(50.0) 
25/46(54.3) 
 
- 
- 
- 
- 
- 
29/46 (63.0) 
 
- 
- 
- 
- 
- 
- 
Co-morbidities: n (%) 
   Hypertension 
   Diabetes mellitus 
   Hypercholesterolemia 
 
18(31.0) 
4(6.9) 
12(20.7) 
 
- 
- 
- 
 
- 
- 
- 
Cushing type: n (%) 
   Pituitary 
   Adrenal 
 
40(69.0) 
18(31.0) 
 
- 
- 
 
- 
- 
"459"
BMI: body mass index; CS: Cushing’s syndrome. 460"
* P<0.05 461"
**P<0.01 462"
Note1: Secondary hypogonadotropic hypogonadism or a postmenopausal state without the use of 463"
chronic estrogen replacement. 464"
  465"
Table 2: Group B (Flow Mediated dilation): Clinical characteristics of patients in long-term remission 466"
of Cushing’s syndrome and healthy controls 467"
 Patients (n=14) Controls (n=14) P-value 
Gender (n): male/ female 2/12 2/12 1.00 
Age at time of test: mean (SD) (years) 46.8 (11.8) 45.7 (10.9) 0.79 
Duration of remission: median (range) 
(years) 
12.9 (4.8-29.4) - - 
BMI: mean (SD) (kg/m2) 25.6 (2.3) 25.6 (2.5) 0.98 
Cushing’s syndrome type: n  
Pituitary 
Adrenal 
 
7  
7  
- - 
Treated hypothyroidism: n  4  - - 
Estrogen status in females: n 
Sufficient 
Insufficient 
 
7  
5  
 
7  
 5  
 
1.00 
BMI: body mass index"468"
" "469"
Table 3: Group B (venous occlusion plethysmography): Clinical characteristics in long-term remission 470"
of Cushing’s syndrome and healthy controls 471"
 Patients (n=11) Controls (n=11) P-value 
Gender (n): male/ female 2/9 2/9 1.00 
Age at time of test: mean (SD) (years) 45.6 (13.2) 45.8 (12.1) 0.98 
Duration of remission: median (range) 
(years) 
 12.8 (4.8-28.8) - - 
BMI: mean (SD) (kg/m2) 25.7 (1.7) 25.3 (2.7) 0.62 
Cushing’s syndrome type: n  
Pituitary 
Adrenal 
 
5  
6  
- - 
Treated hypothyroidism: n  3  - - 
Estrogen status in females: n 
Sufficient 
Insufficient 
 
5  
4  
 
5  
 4  
1.00 
 
BMI: body mass index"472"
" "473"
Table 4:Micro- and macrovascular health parameters in patients in long-term remission of Cushing’s 474"
syndrome and matched controls.  475"
 476"
 477"
Note1 *: For ln-transformed data the geometric means and back-transformed 95%-CI were calculated  478"
to enable clinical interpretation of the outcomes. 479"
Note2: For plaque thickness the comparison between the groups was performed using an unpaired t-480"
test 481"
ICAM-1, intracellular adhesion molecule 1; PAI-1, plasminogen activator inhibitor 1; VCAM-1, 482"
vascular cell adhesion molecule 1; CAP, central augmented pressure; AIx, augmentation index; cIMT, 483"
carotid intima media thickness; PWV, pulse wave velocity; HR75, corrected for a heart rate of 75 484"
beats per minute. FMD, flow mediated dilation; GTN, glyceryltrinitrate; SRAUC, shear rate area under 485"
the curve; CI, confidence interval 486"
  487"
Variable Patients N Controls      N P-value 
GROUP A Mean 95%-CI  Mean 95%-CI   
Serum biomarkers         
*ICAM-1 (pg/ml) 280.4 226.7-346.7 57 314.9 234.7-422.4 57 0.545 
*PAI (pg/ml) 1810.8 1505.8-2163.1 57 1940.5 1653.9-2276.7 57 0.497 
*VCAM-1 (pg/ml) 670.0 615.1-729.9 57 682.4 637.3-730.6 57 0.721 
*E-Selectin (pg/ml) 40.0 35.7-44.6 57 38.5 34.6-43.0 57 0.661 
Non-invasive 
measurements of arterial 
stiffness and 
atherosclerosis 
       
CAP (mmHg) (HR75) 10.1 8.8-11.5 52 9.4 7.6-11.3 52 0.457 
Aortic AIx (HR75) 26.0 23.2-28.8 53 23.1 19.6-26.6 53 0.056 
PWV (m/s) 8.4 8.0-8.9 58 8.3 7.8-8.8 58 0.648 
Mean cIMT (mm) 0.75 0.72-0.78 58 0.75 0.72-0.77 58 0.617 
Plaque thickness (mm) 2.66 1.94-3.38 10 1.95 1.71-2.18 10 0.092 
GROUP B        
Measurements of flow 
mediated dilation 
       
Baseline diameter (mm) 3.60  3.33-3.86 14 3.56  3.30-3.82 14 0.839 
FMD (%) 5.13  4.10-6.15 14 6.22  4.72-7.72 14 0.125 
GTN (%) 18.6  15.5-22.0 14 19.4  15.0-22.9 14 0.691 
Time to peak diameter (s) 40.3  33.4-47.3 14 54.3 42.1-66.6 14 0.059 
SRAUC (s, 103) 30323  25530-35115 14 32164  26471-37857 14 0.597 
Supplemental"table"1:"Outcomes"of"other"cardiovascular"risk"factors"in"patients"and"controls"in"Group"A.""488"
Variable( Controls((n=58)(
(mean)(
SD( Patients(n=58)(
(mean)(
SD(( P7value(
Total(serum(cholesterol((mmol/l)( 5.38" 0.198" 5.16" 0.165" 0.188"
HDL7cholesterol((mmol/l)( "1.44" 0.242" 1.33" 0.216" 0.061"
LDL7cholesterol((mmol/l)( "3.38" 0.255" 3.05" 0.236" 0.055"
Triglycerides((mmol/l)( "1.01" 0.445" 1.43" 0.531" <.001***"
Creatinin((μmol/l)( "68.10" 0.144" 70.81" 0.188" 0.194"
Insulin((mE/l)( 6.51" 0.552" 6.51" 0.722" 0.933"
Hba1c((mmol/mol)( 37.49" 0.088" 39.10" 0.151" 0.355"
Fasting(glucose((mmol/l)( 4.98" 0.107" 4.99" 0.172" 0.973"
HOMA_IR( 1.71" 0.99" 2.36" 5.08" 0.371"
fT4((pmol/l)( 12.28" 0.136" 15.20" 0.202" <.001***"
IGF71((nmol/l)( 16.02" 0.353" 13.25" 0.434" 0.011*"
Systolic(blood(pressure((mmHg)( 132.37" 19.06" 126.04" 14.55" 0.095"
Diastolic(blood(pressure((mmHg)( 77.24" 9.27" 73.85" 9.02" 0.134"
Heart(rate((bpm)( 64.03" 8.42" 66.81" 9.48" 0.151"
Differences)were)tested)by)means)of)paired)t3tests.)For)ln3transformed)data)the)geometric)means)were)calculated)using)489"
back)transformation)to)enable)clinical)interpretation)of)the)outcomes.)HDL,)high)density)lipoprotein;)LDL,)low)density)490"
lipoprotein;)Hba1c,)glycated)hemoglobin;)HOMA_IR,)homeostatic)model)assessment)_)insulin)resistance;)IGF31,)insulin)like)491"
growth)factor)type)1*)p<0.05,)**)p<0.01,)***)p<0.001.)492"
Note"1:"In"our"hospitals"patients"continue"to"visit"our"outpatient"clinic"at"least"once"a"year"after"remission"of"Cushing’s"493"
syndrome"(CS)."During"that"visit"patients"are"screened"for"the"presence"of"hypertension,"diabetes"mellitus"and"494"
hypercholesterolemia."If"needed"treatment"is"initiated."(If"they"already"had"hypertension,"diabetes"mellitus"or"495"
hypercholesterolemia"during"the"active"phase"of"CS,"we"try"to"taper"medication"and"if"possible"to"stop"medication"to"see"if"496"
it"is"still"needed).The"choice"of"which"medication"is"used"was"dependent"on"the"preferences"of"the"individual"physicians"and"497"
patients,"but"usually"metformin"was"the"first"choice"for"diabetes"mellitus"type"2,"simvastatin"was"the"first"choice"for"498"
hypercholesterolemia"and"a"thiazide"diuretic"or"an"aceQinhibitor"were"the"first"choice"for"hypertension."The"effect"of"499"
treatment"was"monitored"regularly"(each"3Q6"months)"and"treatment"was"adjusted"till"treatment"goals"(a"blood"pressure"of"500"
<"140/90"mmHg,"a"HbA1c"<"53"mmol/mol"and"a"LDLQcholesterol"of"<"3.5"mmol/l)"were"reached."501"
Note"2:"In"case"a"patient"had"CS"of"pituitary"origin"biochemical"evaluation"is"carried"out"on"the"fourth"day"postoperatively"to"502"
evaluate"the"function"of"the"pituitary"gland"(after"glucocorticoid"substitution"had"been"stopped"for"at"least"24"hours),"by"503"
measurement"of"fasting"(08:00"h)"plasma"cortisol,"ACTH,"thyrotropin,"free"thyroxine,"gonadotropins,"testosterone"or"504"
estradiol"and"insulinQlike"growth"factor"typeQ1.""If"basal"plasma"cortisol"is"lower"than"200"nmol/l"substitution"therapy"with"505"
hydrocortisone,"30"mg"a"day,"was"prescribed."Patients"were"reQevaluated"every"2–4"weeks"during"the"first"3"months"after"TS"506"
and"thereafter"at"2–3"months"intervals"during"the"first"year."The"fasting"plasma"cortisol"concentration"was"measured"at"507"
each"visit."If"a"patient"received"glucocorticoid"substitution"therapy"postoperatively,"the"dose"was"reduced"and"stopped,"if"508"
possible,"between"3"and"12"months"after"TS."Thereafter"the"integrity"of"the"hypothalamic–pituitary–adrenal"axis"was"509"
assessed"by"an"insulin"tolerance"test."Growth"hormone"deficiency"is"tested"with"a"growth"hormone"stimulation"test."If"a"510"
hormonal"deficiency"is"present"substitution"is"initiated"to"reach"reference"values.""511"
Note"3:"Hypertension"is"defined"as"a"blood"pressure"≥140/90"mmHg."Diabetes"mellitus"is"defined"as"a""HbA1c"≥"6.5%"(≥"48"512"
mmol/mol),"a"fasting"glucose"of""≥7.0"mmol/L""(126"mg/dL")"or"a"non"fasting"glucose"≥11.1"mmol/l"(199"mg/dl)."513"
Hypercholesterolemia"is"defined"as"a"LDL"cholesterol"of">"3.5"mmol/l"or"nonQHDL"cholesterol"of">"4.0"mmol/L"(in"case"no"514"
other"coQmorbidities"are"present;"otherwise"we"use"stricter"criteria).""515"
